“Interest expense increased resulting from interest expense recorded under the effective interest method related to the sale of future royalty liability, higher interest rates on debt balances and lower interest capitalized related to completion of certain pha…”10-Q · Aug 5, 2026 ↗
BeOne Medicines AG
ONC
Market read
BeOne Medicines AG's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 15 directly disclosed connections are confirming.
- Monitor disclosures attributing changes in interest expense to the sale of future royalty liability, higher debt rates, or changes in capitalized interest at Hopewell.
Invalidation: The isolated read changes if ONC's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 15 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- Monitor disclosures attributing changes in interest expense to the sale of future royalty liability, higher debt rates, or changes in capitalized interest at Hopewell.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +40.2% year over year.
- Operating margin changed +23.3 percentage points in the latest annual period.
- Net margin changed +22.3 percentage points in the latest annual period.
- Operating cash flow covered net income at 3.93x in the latest annual period.
- Credit and interest rates has repeated favorable evidence across 5 filings.
- Product pipeline and R&D has repeated favorable evidence across 5 filings.
- Diluted shares increased 7.8% in the latest annual period.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 11, 2026
346.89Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“For the six months ended June 30, 2025, other income, net was $12.1 million, primarily due to foreign exchange gains and government subsidy income, partially offset by unrealized losses on our equity investments.”10-Q · Aug 5, 2026 ↗
“Internal research and development expense increased $111.9 million, or 18.4%, to $718.4 million and was primarily attributable to the expansion of our global development organization and our clinical and preclinical drug candidates, as well as our continued e…”10-Q · Aug 5, 2026 ↗
“Other Expense, Net Other expense, net for the year ended December 31, 2025 was $42.6 million, due to impairment losses recognized on our equity investments partially offset by government subsidy income and foreign exchange gains.”10-K · Feb 26, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 95.8× · EV/sales 95.1×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for ONC. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for ONC. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind ONC
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMGNAmgen Inc.partnerFeb 26, 2026 ▾
“We will share in a portion of the royalties on annual ex-China net revenue from IMDELLTRA ® above $1.5 billion, and will maintain royalty and all other rights to other assets under the terms of the existing collaboration with Amgen, including xaluritamig, a f…”
AMGNAmgen Inc.supplierAug 6, 2025 ▾
“Purchase Commitments As of June 30, 2025, non-cancellable purchase commitments amounted to $130.1 million, of which $32.6 million related to minimum purchase requirements for supply purchased from contract manufacturers and $97.5 million related to binding pu…”
Depended on by
ZYMEZymeworks Inc.partnerMay 7, 2026 ▾
“We have entered into separate collaboration and license agreements with BeOne Medicines Ltd.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ONC is currently a Leader in the organic co-movement group Oncology Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ONC; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.